SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

HIKAL

BSE: 524735 29 Jun 2025
Healthcare
₹ 357.8
Hikal Ltd. specializes in Pharmaceuticals within the Healthcare sector.

HIKAL - Share Price & Details

Market Cap
₹4,432
High /Low
465.0 / 304.0
Stock P/E
48.8
Book Value
₹102.0
Dividend Yield
0.33
ROCE
9.87
ROE
₹7.41
Face Value
2.0
PEG Ratio
-56.8
EVEBITDA
₹15.5
Debt
765
CMP / FCF
95.0
Debt to equity
₹0.61
NP Ann
90.8
High price all time
742.0
Piotroski score
₹7.0
Graham Number
130.0
No. Eq. Shares
12.3
Net CF
₹0.30
Net profit
90.8
Price to book value
3.51
Interest Coverage
₹2.65
Low price all time
15.8
Industry PE
32.0
Reserves
₹1,238
Free Cash Flow
₹144

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
HIKAL LTD.5529.0503.05524.04.084,43248.8
Dishman Carbogen Amcis Limited7243.1430.97163.42.754383
UNICHEM LABORATORIES LTD.5964.3529.75871.87.5416730.3

Peer Comparison Chart


About HIKAL

Hikal Ltd., with Security Code 524735, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Briefs: Hikal and Sun Pharma

(17 Jun 2025)
Hikal completes ANVISA GMP audit of Jigani unit. Hikal Ltd has successfully passed the Brazilian Health Regulatory Agency's (ANVISA) GMP...
Read more →

Hikal Ltd Says Passed Brazilian Anvisa Gmp Audit For Jigani Unit

(16 Jun 2025)
Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals,...
Read more →

Hikal Ltd successfully completes ANVISA GMP audit of Jigani unit

(16 Jun 2025)
Hikal Ltd has successfully passed the Brazilian Health Regulatory Agency's GMP audit for its manufacturing unit located at Jigani in...
Read more →

Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr

(18 May 2025)
In Q4FY25, our crop protection business reported revenue growth of 30% to Rs 201 crore on QoQ basis. By ICN Bureau | May 18, 2025. Hikal Ltd., a preferred...
Read more →

Hikal Q4 Results 2025 – Profit Up 48%, Revenue Grows, Margin Expands | May 2025

(14 May 2025)
Hikal Ltd., a leading provider of specialty chemicals and pharmaceuticals, has announced its financial results for the fourth quarter of...
Read more →

Hikal Ltd's Strong Performance Highlights Resilience in Pharmaceuticals Amid Market Fluctuations

(11 Apr 2025)
Hikal Ltd, a midcap in the Pharmaceuticals & Drugs sector, experienced notable activity on April 11, 2025, with a significant intraday rise.
Read more →